Relation of asymmetric dimethylarginine and cardiac involvement in systemic sclerosis

Basit Öğe Kaydı
dc.contributor.authorDag, Sevin
dc.contributor.authorBudulgan, M.
dc.contributor.authorDilek, B.
dc.contributor.authorBatmaz, I
dc.contributor.authorAriturk, Z.
dc.contributor.authorNas, K.
dc.contributor.authorCevik, R.
dc.date.accessioned2024-04-24T17:37:55Z
dc.date.available2024-04-24T17:37:55Z
dc.date.issued2014
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjectives: The heart is a commonly involved organ in systemic sclerosis (SSc) and pulmonary hypertension is a commonly observed complication that is associated with poor prognosis in this disease. Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of nitric oxide synthases. In this study, we aimed to contribute to an early diagnosis of cardiac involvement by evaluating ADMA and tissue Doppler echocardiographic findings in patients with SSc. Methods: 30 SSc patients without clinical cardiac symptoms and 30 controls were included. Plasma ADMA levels were measured and tissue Doppler echocardiography examination was carried out for all participants. Systolic and diastolic functions were assessed; pulmonary arterial systolic pressure and mean pulmonary arterial pressure were measured. Results: The patient and control groups demonstrated a significant difference with regard to right ventricular free wall tissue Doppler late diastolic wave, pulmonary arterial systolic pressure, right ventricular ejection fraction, and right ventricular diastolic dysfunction values. ADMA levels were significantly higher in SSc patients and also in active patients compared to inactive patients. No significant relationship between ADMA and echocardiographic parameters was found. Conclusion: Tissue Doppler echocardiography is capable of revealing impaired right ventricular functions and increased pulmonary arterial systolic pressure before the occurrence of any cardiac clinical symptoms in patients with SSc. Serum ADMA levels were increased in SSc and in patients with active disease.en_US
dc.identifier.endpage235en_US
dc.identifier.issn0303-464X
dc.identifier.issue3en_US
dc.identifier.pmid25326403
dc.identifier.scopus2-s2.0-84910024718
dc.identifier.scopusqualityQ3
dc.identifier.startpage228en_US
dc.identifier.urihttps://hdl.handle.net/11468/21245
dc.identifier.volume39en_US
dc.identifier.wosWOS:000343367000004
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPublisaude-Edicoes Medicas Ldaen_US
dc.relation.ispartofActa Reumatologica Portuguesa
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSystemic Sclerosisen_US
dc.subjectPulmonary Hypertensionen_US
dc.subjectAsymmetric Dimethylarginineen_US
dc.titleRelation of asymmetric dimethylarginine and cardiac involvement in systemic sclerosisen_US
dc.titleRelation of asymmetric dimethylarginine and cardiac involvement in systemic sclerosis
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu

We collect and process your personal information for the following purposes: Authentication, Preferences, Acknowledgement and Statistics.
To learn more, please read our privacy policy.

Customize